Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Cediranib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 12 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Jul 2017 Planned End Date changed from 31 Jul 2017 to 31 Jul 2019.
- 28 Jul 2017 Planned primary completion date changed from 31 Jul 2017 to 31 Jul 2019.